Company profile
EDGEWISE THERAPEUTICS, INC.
NASDAQ:EWTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SEVASEMTEN | phase2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07795814 | phase2 | recruiting | 2026-08-25 | 2027-12-01 | Edgewise Therapeutics, Inc. | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) |
| NCT07177066 | phase1 | completed | 2025-08-20 | 2026-04-29 | Edgewise Therapeutics, Inc. | A Study of EDG-15400 in Healthy Adults |
| NCT05160415 | phase1 | completed | 2021-12-28 | 2024-03-01 | Edgewise Therapeutics, Inc. | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy |
| NCT05540860 | phase2 | active_not_recruiting | 2022-10-24 | 2027-01-01 | Edgewise Therapeutics, Inc. | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) |
| NCT06347159 | phase2 | active_not_recruiting | 2024-04-11 | 2027-12-01 | Edgewise Therapeutics, Inc. | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) |
FDA applications (0)
No records yet.